Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc. announced that the company was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The combined Phase I/II Fast Track grant will support a clinical trial in ONC201 in advanced brain cancer, furthering the clinical development of the company’s lead compound. ONC201
Hummelstown, PA (March 03, 2015) – Oncoceutics, Inc. is pleased to report that enrollment of the first patient in a clinical trial of ONC201, a novel small molecule anti-cancer drug, is now taking place at Rutgers Cancer Institute of New Jersey. The trial, identified as NCT02250781 on www.clinicaltrials.gov, is entitled “Oral ONC201 in Treating Patients
Hummelstown, PA (February 25, 2015) – Oncoceutics, Inc. announced the publication of a second article in the journal Cancer Research. This new research article, which follows an article published last week on biomarkers and combination therapies, describes the ability of ONC201 to target colorectal cancer stem cells. These findings suggest that ONC201 could improve treatment
Hummelstown, PA (February 16, 2015) – Oncoceutics, Inc. announced the publication of an article in the journal Cancer Research that describes the identification of several predictive markers of ONC201 response in tumor cells and promising drug combinations that may be investigated in future combinatorial clinical studies. Large genetic and pharmacological screens were conducted with ONC201
Business Development